What Happens to Testosterone During Menopause?

What Happens to Testosterone During Menopause?

Testosterone does decline during menopause, but not all at once and not always visibly on a standard lab panel. Levels fall gradually across the decade before and after the final menstrual period, driven by ovarian and adrenal changes — not menopause as a single event. The key caveat: total testosterone can look normal while free testosterone is meaningfully low, because rising SHBG binds more of the hormone. Women with the most noticeable symptoms are often those whose free fraction has quietly collapsed.

---

How Testosterone Changes During the Menopausal Transition

Testosterone in women originates from three sources: the ovaries (~25%), the adrenal glands (~25%), and peripheral conversion of androgen precursors — primarily DHEA and DHEA-S — in fat, muscle, and skin (~50%). During perimenopause and menopause, all three pathways are affected, though at different rates and through different mechanisms.

Ovarian production is partly governed by LH stimulation of theca cells. Although the ovaries don't go completely silent after menopause — they continue secreting androgens for years — their output drops meaningfully as follicular reserves are exhausted. Interestingly, the post-menopausal ovary may still contribute more androgen relative to estrogen than it did during the reproductive years, which is why testosterone doesn't crash the way estradiol does. You can read more about the estrogen side of this picture in our article on what happens to estradiol during menopause.

Adrenal androgen production — primarily DHEA and its sulfated form DHEA-S — declines independently with age through a process sometimes called adrenopause. Peak adrenal androgen output occurs around age 25 and falls by roughly 1–2% per year thereafter. By the time a woman reaches her mid-50s, DHEA-S levels are often 60–80% lower than they were at peak (Labrie et al., Journal of Steroid Biochemistry and Molecular Biology 2003; PMID: 14623515). Since DHEA-S is the primary substrate for peripheral testosterone synthesis, this background decline compounds ovarian losses significantly. If you're tracking DHEA-S on labs, our piece on what happens to DHEA-S levels in menopause walks through normal ranges and what low values mean clinically.

Peripheral conversion is where total testosterone numbers can be misleading. Even when the ovaries and adrenals are producing less, peripheral tissues continue converting DHEA into testosterone and then into estrogens via aromatase. But this conversion is sensitive to adipose tissue volume, insulin resistance, and inflammation — all of which shift during the menopausal transition. Women who develop insulin resistance during this period often show paradoxically elevated total testosterone (a pattern also seen in PCOS, discussed in our article on what happens to testosterone in PCOS), while their free testosterone availability may still be impaired at the tissue level.

The SHBG problem sits at the center of why standard panels miss declining androgen status. Sex hormone-binding globulin binds testosterone tightly, making bound hormone biologically unavailable. SHBG rises with aging, oral estrogen use, and hypothyroidism — all conditions common in the menopausal window. A woman can have a total testosterone of 40 ng/dL (technically within the lab reference range) but a free testosterone below 1.0 pg/mL if SHBG is elevated. For a deeper look at how SHBG shifts during menopause, see our article on what happens to SHBG levels during menopause. The practical implication: always request free testosterone and SHBG alongside total testosterone when evaluating androgen status in midlife women.

---

Symptoms of Low Testosterone in Menopausal Women

The symptom picture of low testosterone in women overlaps substantially with low estrogen and low thyroid — which is part of why it goes undiagnosed. The most commonly reported and clinically studied symptoms include:

• Reduced libido and sexual satisfaction — the most consistent finding across cohort studies
• Fatigue and reduced stamina — distinct from the hot-flash-driven sleep disruption of low estrogen
• Loss of muscle mass and increased fat mass, particularly visceral fat
• Depressed mood, reduced motivation, and cognitive fog
• Thinning skin and hair
• Reduced bone density — testosterone contributes to bone maintenance independently of estrogen

A cross-sectional analysis from the Study of Women's Health Across the Nation (SWAN) found that lower bioavailable testosterone was independently associated with lower sexual desire, even after controlling for estrogen status and psychosocial variables (Randolph et al., Journal of Clinical Endocrinology & Metabolism 2003; PMID: 12915701). This is important: the libido effect of testosterone appears to be additive to, not a substitute for, estrogen's effects.

Muscle and metabolic effects are also well-documented. A randomized controlled trial by Davis et al. found that transdermal testosterone in surgically menopausal women improved lean body mass and reduced fat mass compared to placebo over 12 months, with significant improvements in fatigue and wellbeing scores (Davis et al., Journal of Clinical Endocrinology & Metabolism 2008; PMID: 18000090).

---

Testosterone and Sleep: A Bidirectional Relationship

The relationship between testosterone and sleep in menopausal women is underappreciated. Testosterone is partly secreted in a circadian pattern tied to slow-wave sleep; disrupted sleep suppresses testosterone, and low testosterone impairs sleep architecture. This creates a feedback loop that's difficult to break without addressing both sides.

Data from the SWAN Sleep Study showed that menopausal women with poor sleep quality had significantly lower levels of total and free testosterone compared to those with consolidated sleep, independent of hot flash frequency (Hall et al., Sleep 2009; PMID: 19294959). This matters practically because many women attribute their sleep problems entirely to hot flashes and estrogen deficiency — and miss the androgenic component.

On the intervention side, testosterone replacement in symptomatic post-menopausal women has been associated with improvements in sleep quality and reductions in waking frequency, though the evidence base is smaller than for libido outcomes. Mechanism-wise, testosterone appears to stabilize sleep architecture by modulating GABAergic tone and reducing nighttime cortisol pulses. Managing cortisol is equally important here — chronic stress drives up cortisol and down-regulates androgen output at the hypothalamic level, compounding testosterone loss in women who are already perimenopausal.

---

Does Stress Make Low Testosterone Worse During Menopause?

Yes — and the mechanism is direct, not just correlational. Cortisol and testosterone share a precursor pathway: pregnenolone is the upstream molecule from which both cortisol (via progesterone → cortisol) and DHEA (via DHEA-S → testosterone) are synthesized. Under chronic stress, the adrenal glands prioritize cortisol synthesis, effectively diverting substrate away from the androgen pathway. This is sometimes called "pregnenolone steal," and while the term oversimplifies the enzyme kinetics, the net effect — elevated cortisol suppressing androgen output — is well-supported (Lennartsson & Jonsdottir, Psychoneuroendocrinology 2011; PMID: 21353388).

For menopausal women, this matters acutely because adrenal androgen output is already declining with age. Adding chronic psychological or physiological stress on top of an already-depleted adrenal reserve can produce a pronounced androgen deficit even in women whose ovaries are still functioning. Lifestyle interventions that reduce cortisol — adequate sleep, resistance training, mindfulness, and adaptogenic herbs — may support androgen levels indirectly by relieving adrenal burden.

This is also why perimenopause is a common trigger for women who find that stress seems to amplify every hormonal symptom. The hormonal buffers that existed during reproductive years — higher DHEA-S, more responsive ovarian output — are diminished, leaving the system less resilient to stress-induced disruption. For a parallel look at how stress hormones interact with another key menopausal marker, see our article on what happens to your thyroid during menopause, since thyroid dysregulation can independently suppress free testosterone by raising SHBG.

---

Testosterone Replacement Therapy: What the Evidence Says

Testosterone replacement therapy (TRT) for menopausal women has a more robust evidence base than many clinicians realize, though it remains underutilized due to regulatory gaps — no testosterone product is currently approved specifically for women in the United States, though off-label use is common.

The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, authored by representatives from major endocrine and gynecological societies worldwide, concluded that transdermal testosterone at a dose producing physiological premenopausal levels (free testosterone ~1–3 pg/mL) significantly improves sexual function in postmenopausal women, with a satisfactory short-term safety profile (Davis et al., Journal of Clinical Endocrinology & Metabolism 2019; PMID: 31498418).

Key points from the evidence base:

1. Transdermal delivery (patch or cream) is preferred over oral administration because it avoids first-pass hepatic metabolism, which can otherwise reduce SHBG and alter lipid parameters.
2. Dose matters significantly. Supraphysiological doses (above normal female reference ranges) are associated with acne, hirsutism, and voice changes. Physiological dosing targeting normal female ranges avoids most of these side effects.
3. Combination with estrogen therapy is generally required for women who are also estrogen-deficient; testosterone alone does not address hot flashes, vaginal atrophy, or bone loss from estrogen deficiency.
4. Duration of treatment in most trials is 6–24 months, with benefits sustained across that window and no evidence of breast cancer risk at physiological doses based on current data — though the societies note that long-term data beyond 2 years remain limited.
5. Non-responders are most often women whose free testosterone was not actually low at baseline, women with unaddressed thyroid dysfunction, or women with elevated prolactin suppressing the HPG axis.

For women who are not candidates for or not interested in pharmaceutical TRT, a number of non-hormonal strategies have supporting evidence, discussed in the next section.

---

Supplements to Increase Testosterone: What Has Actual Evidence

The supplement market for testosterone is cluttered with exaggerated claims, but a handful of interventions have credible mechanistic rationale and human trial data specifically relevant to menopausal women.

DHEA deserves particular attention in this context. A meta-analysis of 23 RCTs found that DHEA supplementation in women over 60 produced modest but statistically significant improvements in sexual function, mood, and bone mineral density, with no serious adverse events at doses of 25–50 mg/day (Peixoto et al., Climacteric 2017). Critically, the effect is larger in women who have genuinely low DHEA-S at baseline — which is exactly the population most menopausal women fall into.

Zinc is often overlooked in this context. Zinc is a required cofactor for 5-alpha-reductase and steroidogenic enzymes, and it also inhibits aromatase — the enzyme that converts testosterone to estrogen. In women with low dietary zinc intake, supplementation can measurably raise free testosterone by reducing conversion losses. Marginal zinc deficiency is common in older women due to reduced absorption and lower dietary intake.

Adaptogenic herbs address the stress-cortisol-androgen axis rather than the HPG axis directly. KSM-66 ashwagandha at 600 mg/day reduced serum cortisol by 27.9% in a double-blind RCT of chronically stressed adults, alongside significant improvements in energy and wellbeing (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). For menopausal women whose androgen decline is partly cortisol-mediated, reducing adrenal burden is a legitimate mechanistic strategy.

---

What This Means for Your Formula

Ones analyzes your lab results — including total testosterone, free testosterone, SHBG, DHEA-S, and cortisol — and builds a personalized capsule formula calibrated to what your bloodwork actually shows, not what the average woman your age might need.

For women whose labs indicate low free testosterone with high SHBG or elevated cortisol, three ingredients in the Ones catalog are particularly relevant:

• Ashwagandha KSM-66 at 600 mg — matched to the clinical dose used in the Chandrasekhar et al. 2012 RCT, this targets the cortisol-androgen axis directly. Reducing chronic HPA activation is one of the most evidence-supported non-pharmaceutical strategies for supporting androgen levels in stressed perimenopausal and menopausal women.
• Zinc — dosed to clinical range based on your individual intake and serum status, targeting both enzymatic testosterone synthesis support and aromatase inhibition.
• Rhodiola Rosea — included where adrenal fatigue patterns and high-stress load are present, complementing ashwagandha's cortisol-modulating effect while adding independent fatigue-reduction benefits.

Ones does not stock DHEA directly (it requires practitioner oversight in many jurisdictions), but the AI practitioner flags DHEA-S deficiency in lab findings and includes that in clinical recommendations for follow-up with your provider.

---

Key Takeaways

• Testosterone declines gradually through perimenopause and beyond via three converging pathways: reduced ovarian output, age-related adrenal decline (adrenopause), and downstream effects of SHBG elevation.
• Total testosterone on a standard lab panel frequently looks normal even when free testosterone is significantly low — always request free testosterone and SHBG together.
• Symptoms — including low libido, fatigue, muscle loss, mood changes, and poor sleep — often reflect falling free testosterone even when total levels appear in range.
• Chronic stress makes the problem measurably worse by diverting adrenal precursor substrate (pregnenolone) toward cortisol and away from DHEA and downstream androgens.
• Transdermal testosterone replacement at physiological doses has strong evidence for sexual function outcomes in postmenopausal women per the 2019 Global Consensus Statement, but regulatory gaps mean off-label use requires a knowledgeable prescriber.
• Evidence-backed supplements — including ashwagandha (KSM-66 600 mg), zinc, and rhodiola — can support the androgen pathway indirectly, particularly in women with cortisol elevation or marginal zinc deficiency driving some of the deficit.